Tevimbra is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...

There are many different types of non-Hodgkin lymphoma and the response of patients to treatment depends largely on the type of lymphoma and the stage at which it is diagnosed. Some lymphomas grow ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

Researchers have announced the first new asthma attack treatment in 50 years. The treatment, an injection called benralizumab ...

Ibcasertib is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Non-Hodgkin Lymphoma.

The safety profile was manageable, with common adverse effects including neutropenia, diarrhea, and fatigue, and similar discontinuation rates between treatment arms. This combination therapy may ...

You are at the center of everything we do at Fred Hutch Cancer Center. Here, we surround you with a team of specialists who work together closely to provide expert, targeted care and compassionate ...

ALK-positive NSCLC makes up about 3% to 11% of all lung cancer cases and is often more aggressive, with a higher chance of coming back after treatment and worse results. This highlights the need ...

The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown. Among patients with relapsed or refractory follicular lymphoma (FL), the ...

Randomized Trial of Enhanced Versus Standard Navigation to Promote Timely Initiation of Adjuvant Radiotherapy for Head and Neck Cancer Shaff et al 1 are to be congratulated on their study showing that ...